

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 07-1-2008

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 20-10-2007 TO BE PUBLISHED ON 08-1-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1189/2007	<u>17-10-2007</u> AstraZeneca AB. Sweden. Priority (23-10-2006 USA)	“Chemical Compounds”
1190/2007	Anadys Pharmaceuticals, Inc. USA. Priority (17-10-2006 USA)	“P-toluene sulfuric acid salt of 5-amino-3-(2-o-acetyl-3-deoxy-b-c-ribofuranosyl)-3H-thiazole[4,5-D]pyrimidine-2-one and methods for preparation”
1191/2007	Vertex Pharmaceuticals Incorporated. USA. Priority (31-08-2000 USA) Divisional.	“A pharmaceutically acceptable salt or prodrug of a peptidomimetic compound, process for its preparation and a pharmaceutical composition comprising thereof”
1192/2007	Vertex Pharmaceuticals Incorporated. USA. Priority (31-08-2000 USA) Divisional	“A peptidomimetic compound, process for its preparation and a pharmaceutical composition comprising thereof”
1193/2007	Novartis AG. Switzerland. Priority (18-10-2006 USA)	“Organic compounds”
1194/2007	Oerlikon Textile GmbH & Co. KG. Germany. Priority (19-10-2006 Germany)	“Revolving flat assembly for a carding machine”
1195/2007	Oerlikon Textile GmbH & Co. KG. Germany. Priority (19-10-2006 Germany)	“Revolving flat assembly for a carding machine”
1196/2007	Vertex Pharmaceuticals Incorporated.	“A pharmaceutically acceptable salt or prodrug of a peptidomimetic”

	USA. Priority (31-08-2000 USA) Divisional.	compound, process for its preparation and a pharmaceutical composition comprising thereof
1197/2007	Meiji Dairies Corporation. Japan. Priority (18-10-2006 Japan)	“Food product having recesses”
1198/2007	Kawasaki Plant Systems Kabushiki Kaisha. Japan. Priority (26-12-2006 Japan)	“Waste heat power generation system of cement calcinations plant”
1199/2007	GlaxoSmithKline Consumer Healthcare GmbH & Co. KG. Germany. Priority (20-10-2006 GB)	“Novel Device”
1200/2007	Wyeth. USA. Priority (18-10-2006 USA)	“Processes for the synthesis of individual isomers of mono-peg CCI-779”
	<u>18-10-2007</u>	
1201/2007	Wyeth. USA. Priority (18-10-2006 USA)	“Quinoline compounds”
1202/2007	Elililly and Company. USA. Priority (23-10-2006 USA)	“CB1 Compounds”
1203/2007	Novartis AG. Switzerland. Priority (20-10-2006 USA)	“Crystal modifications”
	<u>19-10-2007</u>	
1204/2007	Shell International Research Maatschappij B.V. Netherlands. Priority (20-10-2006 EP)	“Fuel compositions”
1205/2007	Shell International Research Maatschappij B.V. Netherlands. Priority (20-10-2006 EP)	“Fuel compositions”

1206/2007	Wyeth. USA. Priority (19-10-2006 USA)	“Subfamily-containing derivatives and uses thereof”
1207/2007	AstraZeneca AB. Sweden. Priority (20-10-2006 USA)	“N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide”
1208/2007	Cipla Limited. India. Priority (19-10-2006 India)	“Pharmaceutical compositions and nasal spray incorporating such compositions”
1209/2007	Irm LLC. Bermuda. Priority (20-10-2006 USA)	“Compositions and methods for modulating C-KIT and PDGFR receptors”
1210/2007	Takeda Pharmaceutical Company Limited. Japan. Priority (23-10-2007 USA)	“Mapk/Erk kinase inhibitors”
1211/2007	Sanofi-Aventis. France. Priority (24-10-2006 France)	“Novel fluorine derivatives, compositions containing them and use thereof”
1212/2007	Takeda Pharmaceutical Company Limited. Japan. Priority (25-10-2006 Japan)	“Metastin derivatives and use thereof”
1213/2007	<u>20-10-2007</u> Leco Stationery Manufacturing Company Limited. Hong Kong. Priority (23-10-2006 China)	“Paper fastener”
1214/2007	Smithkline Beechm Corporation. USA. Priority 24-10-2006 USA)	“Farnesoid X receptor agonists”
1215/2007	Elililly and Company. USA. Priority (20-11-2006 USA)	“Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators”

1216/2007 1. Cytokinetics, Inc.
USA.
2. SmithKline Beecham
Corporation.
USA.
Priority (06-05-2004 USA)
Divisional.

“A pharmaceutically acceptable salt of
a substituted N-phenethylbenzamide
inhibitor of the mitotic kinesin
centromere-associated protein-e(CENP-
E)”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

1013/2005 Unilever Plc.
United Kingdom

“Consumable composition with antioxidant comprising theaflavin thearubigin and catechin ”

(CO7D 311/62, A23F 3/16)

139317

A consumable composition with antioxidant is described. The consumable composition comprises theaflavin, thearubigin and catechin and has good taste and appearance characteristics. The consumable composition can be black tea having green tea catechins as additives.

1251/2005 Clariant International Ltd. “Dispersant for polyester oligomer”
Switzerland

(D06M 101/32, D06M 13/272)

139318

The present invention relates to the use of mono- or polyunsaturated alpha-olefmsulphonates as an active substance alone or in combination with further codispersants for removing polyester oligomers from fibres, fabrics or textile-dyeing machines, for preventing deposits or for deweighting polyester fibres.

XXXXXXXXXXXXXXXXXX